OCS ▼ -1.4% - Oculis Holding AG $OCS - Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease 19-OCT-2026 02:00 AM ET